DEALS

Zhong Lun Advises on Structure Therapeutics' IPO on Nasdaq

Release time：2023-02-06 Voice Announcements

On February 3, 2023, Structure Therapeutics Inc. (Nasdaq: GPCR) announced its initial public offering and listing of American depositary shares on the Nasdaq Global Market. The total offering size will be approximately US$161.1 million prior to the exercise of the over-allotment option. Jefferies, SVB Securities, Guggenheim Securities and BMO Capital Markets acted as the joint bookrunners for this offering.

Structure Therapeutics is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its initial focus is on G-protein-coupled receptors as a therapeutic target class.

Zhong Lun Law Firm acted as the PRC legal advisor to the issuer in this offering. The legal team from Zhong Lun was led by Anthony Zhao and William Jia, and included Roy Zheng, Ruby Zheng, etc. Jerry Fang also provided support in his area of expertise.

Previous：Zhong Lun Assists Hony Green Venture Fund to Lead Investment in Epkeeper's over RMB 100 Million Series B Financing Next：Zhong Lun Assists Kakao in Defending Rights over its Repeatedly Preemptively-registered Well-known Trademarks

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Law Firm Assists Protective Industrial Products to Acquire Honeywell’s Personal Protective Equipment Business

Zhong Lun Assists LaNova Medicines in Completing its CNY 300 Million Series C1 Financing and Entering into Strategic Collaboration with Sino Biopharm

Events

Awards

Zhong Lun Advises on Structure Therapeutics' IPO on Nasdaq